ArticleMicrobiology spectrum2025
African swine fever virus MGF505-3R facilitates ferroptosis to restrict TBK1-IRF3 pathway.
Article in Microbiology spectrum, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Exploiting Ubiquitination: African Swine Fever Virus-Mediated Recruitment of Host E3 Ligases During Viral Infection and Immune Regulation.Pathogens (Basel, Switzerland) · 2026Review
- Host-pathogen interactions in African swine fever: From viral entry to systemic disease progression.Cell insight · 2026Review
- Hairpin loop to hairpin loop: a full-length assembly of the ASFV genome using Oxford Nanopore long-read sequencing.Frontiers in microbiology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
African swine fever virus (ASFV) causes hemorrhagic, severe infectious diseases and serious economic losses to the pig industry. ASFV multigene family 505 can antagonize the host's innate immunity through multiple signaling pathways and is considered an important target for vaccine development. However, the mechanism by which it induces host cell damage remains unclear. In this study, we observed that ASFV infection, similar to RSL3, can induce ferroptosis with the accumulation of reactive oxygen species (ROS) and iron, decrease glutathione peroxidase 4 (GPX4) expression, and restrain the Kelch-like ECH-associated protein 1-nuclear factor E2-related factor (Keap1-Nrf2) pathway. Moreover, the expression of ferroptosis biomarkers (LOX and PTGS2) has been moderately upregulated. Some proteins related to ASFV replication, invasion, and infection were evaluated for evidence of ferroptosis. MGF505-3R interacts with GPX4 to undergo ferroptosis, resulting in ROS accumulation, mitochondrial membrane potential destruction, and NCOA4-mediated ferritinophagy elevation. In addition, MGF505-3R suppressed the Keap1-Nrf2 pathway, while GPX4 activation counteracted its stimulatory effect on TANK-binding kinase 1 (TBK1)-IRF3 phosphorylation. Importantly, the transcription levels of interferon beta (IFN-β), ISG15, and ISG54 were elevated after GPX4 activation, suggesting that ferroptosis resistance could reverse the inhibition of the TBK1-IRF3 pathway and IFN-β levels induced by MGF505-3R. These findings provide new ideas and directions for elucidating the mechanism of ASFV-induced oxidative damage and lay a significant foundation for revealing the pathogenic mechanism of the virus by targeting ferroptosis. IMPORTANCE: We revealed that ASFV infection and MGF505-3R transfection induced the accumulation of iron and ROS, resulting in NCOA4-mediated ferritinophagy and ferroptosis, as well as restricted GPX4 expression and the Keap1-Nrf2 pathway. GPX4 activation promotes the TBK1-IRF3-IFN-β pathway and exerts antiviral activity. These findings indicate that ASFV facilitates ferroptosis, providing a proof of principle that may be applicable to oxidative damage and lipid peroxidation manipulation-based therapy for ASFV infection. Given the GPX4 downregulation in ASFV infection, GPX4 activation and ferroptosis resistance highlight its potential as a therapeutic target for viral infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.